Last reviewed · How we verify

Split dose of methadone — Competitive Intelligence Brief

Split dose of methadone (Split dose of methadone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist. Area: Addiction Medicine / Pain Management.

marketed Opioid agonist Mu opioid receptor Addiction Medicine / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Split dose of methadone (Split dose of methadone) — Wake Forest University Health Sciences. Split-dose methadone divides the daily methadone dose into multiple administrations to optimize plasma levels and reduce peak-trough fluctuations.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Split dose of methadone TARGET Split dose of methadone Wake Forest University Health Sciences marketed Opioid agonist Mu opioid receptor
NALBUPHINE HYDROCHLORIDE NALBUPHINE HYDROCHLORIDE marketed kappa opioid receptors, mu opioid receptors 1979-01-01
Tylenol with codeine Tylenol with codeine National Center for Complementary and Integrative Health (NCCIH) marketed Opioid analgesic combination Mu opioid receptor (codeine); cyclooxygenase enzymes (acetaminophen)
Morphine and Midazolam Morphine and Midazolam Ain Shams University marketed Opioid analgesic and benzodiazepine sedative combination Mu opioid receptor; GABA-A receptor
Hyperbaric bupivacaine+Morphine Hyperbaric bupivacaine+Morphine Fundación Pública Andaluza Progreso y Salud marketed Local anesthetic + opioid combination Voltage-gated sodium channels (bupivacaine); mu opioid receptors (morphine)
PCM/Oxy1 PCM/Oxy1 Maastricht University Medical Center marketed Opioid analgesic combination Mu opioid receptor (oxycodone); COX enzymes (paracetamol)
Methadone Maintenance Therapy Methadone Maintenance Therapy Oregon Health and Science University marketed Synthetic opioid agonist Mu opioid receptor (μ-opioid receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist class)

  1. University of British Columbia · 3 drugs in this class
  2. Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
  3. Kaohsiung Veterans General Hospital. · 2 drugs in this class
  4. Nycomed · 2 drugs in this class
  5. Rigshospitalet, Denmark · 2 drugs in this class
  6. University Hospital, Ghent · 2 drugs in this class
  7. Fundación Universitaria de Ciencias de la Salud · 2 drugs in this class
  8. Erasme University Hospital · 2 drugs in this class
  9. Cephalon · 2 drugs in this class
  10. Corporacion Parc Tauli · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Split dose of methadone — Competitive Intelligence Brief. https://druglandscape.com/ci/split-dose-of-methadone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: